Treatment of Bladder Cancer After Platinum and PD-1/L1 Inhibitor Therapy: Real-World Outcomes
Posted: Tuesday, November 16, 2021
Recent findings published in Future Oncology suggest that patients with locally advanced or metastatic urothelial carcinoma tend to have a short duration of real-world survival outcomes following platinum and PD-1/L1 inhibitor therapy. According to Katherine Tan, PhD, of Flatiron Health, New York, and colleagues, the study represents the largest real-world data set on survival in this population to date .
Study data were collected from the Flatiron Health nationwide electronic health record–derived U.S. oncology database, which encompasses more than 280 cancer clinics. The study population comprised two cohorts: patients treated with taxane monotherapy (n = 72) and patients who received any therapy post PD-1/L1 inhibitor treatment (n = 208). In both cohorts, patients had to have had prior platinum-containing chemotherapy and PD-1/L1 inhibitor therapy to be eligible.
In the taxane-monotherapy cohort, median real-world overall survival was 7.6 months (95% confidence interval [CI] = 5.2–14.4 months), and the 6-month survival probability was rated at 56% (95% CI = 45–70%). The median real-world progression-free survival was 2.9 months (95% CI = 2.4–4.0 months), and the 6-month real-world progression-free survival probability was 26% (95% CI = 17–40%). In comparison, the any-therapy cohort had a median real-world overall survival of 8.9 months (95% CI = 7.3-10.6 months) and a 6-month survival probability of 63% (95% CI = 56–71%). The median real-world progression-free survival was 3.6 months (95% CI = 2.7–4.7 months), and the 6-month real-world progression-free survival probability was 37% (95% CI = 30–45%).
“Among patients who do receive subsequent therapy, real-world outcomes, as determined by real-world progression-free survival and real-world overall survival, are poor,” the study authors commented. “Novel and effective therapeutic options should be considered in this patient population,” they concluded.
Disclosure: For full disclosures of the study authors, visit futuremedicine.com.